ArticleGenes & genomics2022
Centromere protein N promotes lung adenocarcinoma progression by activating PI3K/AKT signaling pathway.
Article in Genes & genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- MiR-138-5p Suppresses Glucose Metabolism to Inhibit the Progression of Nasopharyngeal Carcinoma by Targeting the CENPN/PI3K/Akt/mTOR Signaling.Journal of biochemical and molecular toxicology · 2026Article
- Article
- Integrated bioinformatics and tissue-based validation reveal the oncogenic role of hsa_circ_0043256 and hsa_circ_0004789 in gastric cancer.Biochemistry and biophysics reports · 2026Article
- Diagnostics and immunological function of CENPN in human tumors: from pan-cancer analysis to validation in breast cancer.Translational cancer research · 2025Article
- CENPN contributes to pancreatic carcinoma progression through the MDM2-mediated p53 signaling pathway.Archives of medical science : AMS · 2024Article
- Clinical implications and immune features of CENPN in breast cancer.BMC cancer · 2023Article
- High expression of centromere protein N as novel biomarkers for gastric adenocarcinoma.Cancer reports (Hoboken, N.J.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs an important member of centromere family, centromere associated protein N (CENPN) was abnormally expressed in varied malignant tumors.
objectiveThis paper aimed to analyze the expression and related mechanism of CENPN in lung adenocarcinoma (LUAD).
methodsThe expression of CENPN in LUAD was analyzed by Gene Expression Profiling Interactive Analysis (GEPIA) database. The mRNA expression, protein expression, cell viability, cell invasion, cell apoptosis, cell stem like characteristics were detected by RT-PCR, western blot, CCK8 assay, transwell assay, flow cytometry and spheroidization assay, respectively. Finally, the pathological changes of xenograft were estimated by H&E staining, and the expression of proteins was detected by immunohistochemistry.
resultsGEPIA analysis showed that the CENPN expression in LUAD was significantly higher than that in normal lung tissue, which was negatively correlated with the prognosis. These results were consistent with our clinical data. Besides, CENPN was highly expressed in LUAD cell lines. In addition, the upregulation of CENPN amplified the cell viability, stemness and invasive ability in PC9 cells. However, the knockdown of CENPN inhibited the cell activity, stemness, invasive ability with increased cell apoptosis in A549. Furthermore, CENPN could positively regulate the phosphorylation of PI3K and AKT. The PI3K inhibitor, 740Y-P, could reverse the effect of CENPN silencing on the expression of Ki-67, cleaved caspase 3, OCT4, and snail 1. Finally, the downregulation of CENPN restrained the growth of xenograft and inactivated the PI3K/AKT pathway.
conclusionCENPN was abnormally overexpressed in LUAD, and promoted tumor progression of LUAD by affecting PI3K/AKT pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.